[HTML][HTML] Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective

SJ Modi, VM Kulkarni - Medicine in Drug Discovery, 2019 - Elsevier
New blood vessels formation from the existing vasculature is called angiogenesis. It is an
essential physiological process for the growth of cells, tissue repair, wound healing, and …

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review

C Wang, Y Zhang, T Zhang, J Xu, S Yan, B Liang… - International Journal of …, 2023 - Elsevier
Overexpression of the epidermal growth factor receptor (EGFR) has been linked to several
human cancers, including esophageal cancer, pancreatic cancer, anal cancer, breast …

Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors

MA Zeidan, AS Mostafa, RM Gomaa… - European journal of …, 2019 - Elsevier
Two series of picolinamide derivatives bearing (thio) urea and dithiocarbamate moieties
were designed and synthesized as VEGFR-2 kinase inhibitors. All the new compounds were …

Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2

HQ Zhang, FH Gong, JQ Ye, C Zhang, XH Yue… - European Journal of …, 2017 - Elsevier
EGFR and VEGFR-2 are involved in pathological disorders and the progression of different
kinds of tumors, the combined blockade of EGFR and VEGFR signaling pathways appears …

Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors

HQ Zhang, FH Gong, CG Li, C Zhang, YJ Wang… - European journal of …, 2016 - Elsevier
Both EGFR and VEGFR-2 are important targets for cancer therapy, the combined inhibition
of both EGFR and VEGFR-2 signaling pathway represents a promising approach to the …

Discovery of novel anti-angiogenesis agents. Part 11: development of PROTACs based on active molecules with potency of promoting vascular normalization

Y Shan, R Si, J Wang, Q Zhang, J Li, Y Ma… - European Journal of …, 2020 - Elsevier
Our recent investigation is focused on the discovery of anti-angiogenesis agents. Vascular
normalization induced by anti-angiogenic agent appears to be a promising strategy. We …

Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo [3, 4-d] pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors

Y Wang, S Wan, Z Li, Y Fu, G Wang, J Zhang… - European Journal of …, 2018 - Elsevier
Aiming to explore novel BRAF V600E and VEGFR-2 dual inhibitors, a series of 1H-pyrazolo
[3, 4-d] pyrimidine derivatives were designed, synthesized and biologically evaluated in this …

Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors

Y Sun, Y Shan, C Li, R Si, X Pan, B Wang… - European Journal of …, 2017 - Elsevier
Abstract VEGFR-2, TIE-2, and EphB4 are essential for both angiogenesis and
tumorigenesis. Herein, we designed and prepared three classes of multi-target inhibitors …

Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl) vinyl) quinoxalinone derivates as potent VEGFR-2 kinase inhibitors

L Shi, J Zhou, J Wu, J Cao, Y Shen, H Zhou… - Bioorganic & Medicinal …, 2016 - Elsevier
Inhibition of VEGFR-2 kinase has been highlighted as one of the well-defined strategies to
suppress tumor growth via blockade of angiogenesis. Guided by the principles of …

Antiangiogenic compounds: well-established drugs versus emerging natural molecules

A Ribeiro, RMV Abreu, MM Dias, MF Barreiro… - Cancer Letters, 2018 - Elsevier
Angiogenesis is the natural and physiologic process of growing blood vessels from pre-
existing ones. Pathological angiogenesis occurs when the precise balance of all the …